On July 1, 2026, RenovoRx, Inc. received notification from Nasdaq that it remains non-compliant with the $1.00 minimum bid price requirement. However, Nasdaq granted the company a second 180-calendar day compliance period, extending the deadline to regain compliance to December 28, 2026. To avoid delisting, the common stock must maintain a closing bid price of at least $1.00 for 10 consecutive business days. The company operates in the biotechnology industry and develops medical devices for drug delivery.
